Browse the evidence

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

There were no significant between-group differences in VAT volume after 6 months or 12 months.

Dietary interventions may not differ significantly in their effects on VAT volume over time.

Statins have not mitigated the incidence or prevalence of cardiovascular disease (CVD).

Practitioners should reconsider the reliance on statins for CVD prevention.

Demographics associated with higher prescription period prevalence included non-Hispanic Black race and ethnicity, female sex, and older age.

Understanding these demographic factors can help tailor interventions and support for specific groups.

Semaglutide is available in two formulations: once-weekly subcutaneous and once-daily oral.

Practitioners can offer patients a choice between two formulations of semaglutide for weight management.

There was no significant difference in weight loss between the intervention and control groups at 6 months (P=0.26).

Inpatient obesity interventions with postdischarge follow-up may not lead to significant weight loss.

There were no differences in waist-to-hip ratios between the intervention and control at 6 months.

The intervention did not affect waist-to-hip ratios, indicating no change in body composition.

The ten largest food companies in the United States control over half of all food sales.

Practitioners should be aware of the significant market power held by a few companies in the food industry.

Worldwide, the largest food companies control about 15% of food sales, and this proportion is rising.

Practitioners should consider the increasing influence of major companies on global food systems.

More than half of global soft drinks are produced by large multinational companies, mainly Coca-Cola and PepsiCo.

Practitioners should recognize the significant market share held by major soft drink companies.

Only 8% of eligible candidates with type 2 diabetes are prescribed GLP-1RA.

Cardiologists should be aware of the low prescription rates of GLP-1RA among eligible patients.

The uptake of GLP-1RA in clinical practice is low among cardiologists.

Efforts are needed to increase awareness and education among cardiologists regarding GLP-1RA.

If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.

Understanding these cost projections is crucial for policymakers and healthcare planners.

Concerns regarding operative risks, irreversibility, and excess costs limit the broader clinical use of metabolic and bariatric surgeries.

Practitioners should be aware of these concerns when discussing surgical options with patients.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

The prevalence of obesity in the United States is 35.0% for men and 40.4% for women based on 2013 to 2014 national survey data.

Health practitioners should be aware of the significant prevalence of obesity in the population.

Body mass index (BMI) requirements for gender-affirming surgeries (GAS) present an obstacle to gender transition for many transgender and gender diverse (TGD) people.

Clinicians should be aware of the BMI-related barriers faced by TGD patients when considering GAS.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

Calorie restriction does not significantly interact with BMI stratum in affecting cognitive outcomes.

BMI does not appear to influence the cognitive effects of CR in this study.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend=0.38).

Dietary recommendations regarding rice consumption may not apply uniformly across different populations, such as in China.